Risankizumab
Skyrizi (risankizumab) is an antibody pharmaceutical. Risankizumab was first approved as Skyrizi on 2019-04-23. It is used to treat psoriasis in the USA. It has been approved in Europe to treat psoriasis and psoriatic arthritis. It is known to target interleukin-23 subunit alpha.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| musculoskeletal diseases | D009140 |
| skin and connective tissue diseases | D017437 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| skyrizi | Biologic Licensing Application | 2024-06-18 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
90 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Psoriasis | D011565 | EFO_0000676 | L40 | 2 | 4 | 17 | 8 | 11 | 42 |
| Crohn disease | D003424 | EFO_0000384 | K50 | 2 | 4 | 7 | 2 | 7 | 21 |
| Inflammatory bowel diseases | D015212 | EFO_0003767 | — | 1 | 1 | 1 | 1 | 1 | 4 |
| Intestinal diseases | D007410 | HP_0002242 | K63.9 | 1 | 1 | — | 1 | — | 2 |
| Recurrence | D012008 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Psoriatic arthritis | D015535 | EFO_0003778 | L40.5 | 2 | 2 | 5 | — | 3 | 12 |
| Arthritis | D001168 | HP_0001369 | M05-M14 | 1 | 2 | 5 | — | 2 | 10 |
| Ulcerative colitis | D003093 | EFO_0000729 | K51 | 2 | 2 | 2 | — | 2 | 6 |
| Colitis | D003092 | EFO_0003872 | K52.9 | 1 | 1 | 2 | — | — | 3 |
| Ulcer | D014456 | MPATH_579 | — | 1 | 1 | 2 | — | — | 3 |
| Juvenile arthritis | D001171 | EFO_1002007 | M08 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | — | — | — | 1 | — | — | — | 1 |
| Hidradenitis suppurativa | D017497 | — | L73.2 | — | 1 | — | — | — | 1 |
| Hidradenitis | D016575 | — | — | — | 1 | — | — | — | 1 |
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | — | 1 | — | — | — | 1 |
| Eczema | D004485 | HP_0000964 | L30.9 | — | 1 | — | — | — | 1 |
| Dermatitis | D003872 | HP_0011123 | L30.9 | — | 1 | — | — | — | 1 |
| Asthma | D001249 | EFO_0000270 | J45 | — | 1 | — | — | — | 1 |
| Ankylosing spondylitis | D013167 | EFO_0003898 | M45 | — | 1 | — | — | — | 1 |
| Spondylarthritis | D025241 | — | — | — | 1 | — | — | — | 1 |
| Spondylitis | D013166 | — | M46.9 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 12 | — | — | — | — | 12 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Inflammation | D007249 | MP_0001845 | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Risankizumab |
| INN | risankizumab |
| Description | Skyrizi (risankizumab) is an antibody pharmaceutical. Risankizumab was first approved as Skyrizi on 2019-04-23. It is used to treat psoriasis in the USA. It has been approved in Europe to treat psoriasis. It is known to target interleukin-23 subunit alpha. |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL3990029 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB14762 |
| UNII ID | 90ZX3Q3FR7 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
IL23A
IL23A
Organism
Homo sapiens
Gene name
IL23A
Gene synonyms
SGRF
NCBI Gene ID
Protein name
interleukin-23 subunit alpha
Protein synonyms
IL-23 subunit alpha, IL-23-A, IL-23p19, interleukin 23 p19 subunit, interleukin 23, alpha subunit p19, Interleukin-23 subunit p19, interleukin-six, G-CSF related factor, JKA3 induced upon T-cell activation
Uniprot ID
Mouse ortholog
Il23a (83430)
interleukin-23 subunit alpha (Q9EQ14)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Skyrizi – AbbVie
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,136 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
41,112 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use